Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (2601)	11/2/2010 5:32:31 PM
From: rkrw	1 Recommendation of 3027

Every brand company does everything they can do to prevent generic competition. File a series of weak patents, sue everyone for infringement, go for new formulations and new i.p and if all else fails, file aggressive Citizen's Petitions and settle to push it out a little bit more. I'm not quite sure what the generic Copaxone threat has to do with Teva seeking approval for generic Lovenox other than mnta is involved with both. The filing is already in and it's not as if a court case costs all that much money relatively. If Momenta hadn't filed on Copaxone would Teva be guiding analysts to not expect Lovenox approval?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next